nicotine has been researched along with nortriptyline in 48 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.25) | 18.2507 |
| 2000's | 31 (64.58) | 29.6817 |
| 2010's | 13 (27.08) | 24.3611 |
| 2020's | 1 (2.08) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 1 |
| Dansette, PM; Fontana, E; Poli, SM | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahman, M; Holmén, AG; Wan, H | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Benowitz, NL | 1 |
| Fryer, GE; Keller, RT; Licari, PA; Lofaso, D; Prochazka, AV; Weaver, MJ | 1 |
| Bernabei, R; Gambassi, G | 1 |
| Hall, SM; Hartz, DT; Humfleet, GL; Muñoz, RF; Reus, VI; Tsoh, JY | 1 |
| Kurasawa, M; Nakamura, K | 1 |
| Coleman, T | 1 |
| DeGraff, AC | 1 |
| Hatsukami, DK; Kotlyar, M | 1 |
| Cullen, J; Hall, SM; Humfleet, GL; Muñoz, RF; Reus, VI | 1 |
| Fryer, GE; Kick, S; Miyoshi, T; Prochazka, AV; Steinbrunn, C | 1 |
| McNee, W; Metcalfe, S; Moodie, P | 1 |
| Schroeder, SA | 1 |
| Foulds, J; Steinberg, MB; Williams, JM; Ziedonis, DM | 1 |
| Corelli, RL; Hudmon, KS | 1 |
| Hill, A | 1 |
| Duquet, N | 1 |
| Cofta-Woerpel, L; Wetter, DW; Wright, KL | 1 |
| Frishman, WH | 1 |
| Shoaib, M; Wing, VC | 2 |
| Hoogendoorn, M; Rutten-van Mölken, MP; Welsing, P | 1 |
| Campbell, LA; Kisely, S | 1 |
| David, SP; Munafò, MR | 1 |
| Aveyard, P; Fillingham, S; Johnson, C; Murphy, M; Parsons, A | 1 |
| Chavannes, NH; Frijling, BD; Goudswaard, AN; Kaper, J; van der Laan, JR; Wiersma, T; Wind, LA | 1 |
| Bredesen, H; Lous, J | 1 |
| Bau, CH; Bizarro, L; Dobler, CJ; Kortmann, GL | 1 |
| Deissenrieder, F; Groneberg, D; Kusma, B; Mache, S; Quarcoo, D; Welte, T | 1 |
| Berlin, I | 1 |
| Bhat, A; Crain, D | 1 |
| Herman, AI; Sofuoglu, M | 1 |
| Arrabal-Fernandes, FL; Bussacos, MA; Lombardi, EM; Prado, GF; Santos, Ude P; Terra-Filho, M | 1 |
| Belcon, AL | 1 |
| Ebbert, JO; Elrashidi, MY | 1 |
| Andrade, AG; Bhugra, D; Carvalho, CFC; Castaldelli-Maia, JM; Frallonardo, FP; Gil, F; Guimarães-Pereira, BBS; Ismael, F; Loreto, AR; Richter, KP; Ventriglio, A | 1 |
| Agrawal, S; Aveyard, P; Fanshawe, TR; Freeman, SC; Hajizadeh, A; Hartmann-Boyce, J; Lindson, N; Livingstone-Banks, J; Ordóñez-Mena, JM; Sutton, AJ; Theodoulou, A; Zhu, S | 1 |
15 review(s) available for nicotine and nortriptyline
| Article | Year |
|---|---|
Cytochrome p450 enzymes mechanism based inhibitors: common sub-structures and reactivity.
Topics: Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Humans; Isoenzymes; Structure-Activity Relationship; Terminology as Topic | 2005 |
Smoking cessation: integrating recent advances into clinical practice.
Topics: Administration, Cutaneous; Antidepressive Agents; Bupropion; Ganglionic Stimulants; Health Education; Health Policy; Humans; Motivation; Nicotine; Nortriptyline; Smoking Cessation; Smoking Prevention; Substance-Related Disorders; United Kingdom | 2001 |
Managing nicotine addiction.
Topics: Administration, Inhalation; Adolescent; Adult; Antidepressive Agents, Tricyclic; Bupropion; Chewing Gum; Clonidine; Drug Combinations; Female; Humans; Logistic Models; Nicotine; Nicotinic Agonists; Nortriptyline; Pregnancy; Smoking; Sympatholytics; Tobacco Use Cessation; Tobacco Use Disorder; United States; United States Agency for Healthcare Research and Quality; Women's Health | 2002 |
Developments in pharmacotherapy for tobacco dependence: past, present and future.
Topics: Adolescent; Adult; Bupropion; Clinical Trials as Topic; Clonidine; Drug Administration Routes; Female; Humans; Male; Nicotine; Nicotinic Agonists; Nortriptyline; Pregnancy; Smoking Cessation; Smoking Prevention; Treatment Outcome | 2006 |
Pharmacologic interventions for smoking cessation.
Topics: Administration, Cutaneous; Administration, Inhalation; Antidepressive Agents, Second-Generation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Critical Care; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Nurse's Role; Patient Education as Topic; Patient Selection; Phytotherapy; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Smoking Prevention; United States; United States Food and Drug Administration; Varenicline | 2006 |
A cost-effectiveness evaluation of single and combined smoking cessation interventions in Texas.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Bupropion; Clonidine; Cost-Benefit Analysis; Decision Trees; Drug Therapy, Combination; Health Care Costs; Humans; Nicotine; Nortriptyline; Smoking; Smoking Cessation; Texas; Tobacco Use Disorder; Treatment Outcome | 2006 |
[Quit smoking is not just a matter or will].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Humans; Nicotine; Nortriptyline; Smoking Cessation; Tobacco Use Disorder | 2006 |
Smoking cessation 3: multicomponent interventions.
Topics: Behavior Therapy; Bupropion; Clonidine; Combined Modality Therapy; Humans; Motivation; Nicotine; Nortriptyline; Psychotherapy, Brief; Smoking Cessation; Tobacco Use Disorder | 2007 |
Smoking cessation pharmacotherapy--nicotine and non-nicotine preparations.
Topics: Administration, Cutaneous; Administration, Inhalation; Benzazepines; Bupropion; Chewing Gum; Clonidine; Coronary Artery Disease; Humans; Monoamine Oxidase Inhibitors; Nicotine; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Receptors, Nicotinic; Rimonabant; Selective Serotonin Reuptake Inhibitors; Smoking; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder; Tobacco, Smokeless; Varenicline | 2007 |
Use of smoking cessation therapies in individuals with psychiatric illness : an update for prescribers.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Dopamine Uptake Inhibitors; Drug Prescriptions; Humans; Mental Disorders; Nicotine; Nortriptyline; Smoking Cessation; Tobacco Use Disorder | 2008 |
Pharmacogenetics of smoking cessation therapy.
Topics: Benzazepines; Bupropion; Clonidine; Genome-Wide Association Study; Humans; Nicotine; Nortriptyline; Pharmacogenetics; Quinoxalines; Smoking Cessation; Varenicline | 2010 |
Therapeutic strategies to optimize the efficacy of nicotine replacement therapies.
Topics: Administration, Cutaneous; Administration, Oral; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Humans; Nicotine; Nortriptyline; Pulmonary Disease, Chronic Obstructive; Smoking Cessation; Smoking Prevention; Tobacco Use Disorder | 2009 |
Comparison of available treatments for tobacco addiction.
Topics: Behavior Therapy; Benzazepines; Bupropion; Humans; Nicotine; Nortriptyline; Quinoxalines; Smoking Cessation; Tobacco Use Disorder; Treatment Outcome; Varenicline | 2010 |
Emerging drugs for the treatment of tobacco dependence: 2014 update.
Topics: Atomoxetine Hydrochloride; Benzazepines; Bupropion; Clinical Trials as Topic; Clonidine; Humans; Mecamylamine; Nicotine; Nortriptyline; Propylamines; Quinoxalines; Tobacco Use Cessation Devices; Tobacco Use Disorder; Varenicline | 2014 |
Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.
Topics: Adult; Bupropion; Electronic Nicotine Delivery Systems; Female; Humans; Network Meta-Analysis; Nicotine; Nortriptyline; Pregnancy; Smoking Cessation; Varenicline | 2023 |
5 trial(s) available for nicotine and nortriptyline
| Article | Year |
|---|---|
A randomized trial of nortriptyline for smoking cessation.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Antidepressive Agents, Tricyclic; Double-Blind Method; Female; Humans; Male; Middle Aged; Nicotine; Nortriptyline; Smoking Cessation; Substance Withdrawal Syndrome; Treatment Outcome | 1998 |
Pharmacologic therapy for nicotine addiction.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Double-Blind Method; Humans; Male; Middle Aged; Nicotine; Nortriptyline; Smoking; Smoking Cessation; Tobacco Use Disorder | 2002 |
Extended nortriptyline and psychological treatment for cigarette smoking.
Topics: Administration, Cutaneous; Adult; Antidepressive Agents, Tricyclic; Behavior Therapy; Combined Modality Therapy; Counseling; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Nicotine; Nortriptyline; Placebos; Psychotherapy, Group; Smoking Cessation; Smoking Prevention; Treatment Outcome | 2004 |
A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation.
Topics: Administration, Cutaneous; Administration, Oral; Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nicotine; Nortriptyline; Probability; Reference Values; Risk Assessment; Smoking; Smoking Cessation; Statistics, Nonparametric; Substance Withdrawal Syndrome; Treatment Outcome | 2004 |
Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Tricyclic; Behavior Therapy; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Nicotine; Nicotinic Agonists; Nortriptyline; Quality of Life; Smoking Cessation; Smoking Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2008 |
28 other study(ies) available for nicotine and nortriptyline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
Topics: Brain; Central Nervous System; Chromatography, Liquid; Emulsions; Mass Spectrometry | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Treating tobacco addiction--nicotine or no nicotine?
Topics: Antidepressive Agents; Bupropion; Humans; Nicotine; Nortriptyline; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 1997 |
Antidepressants and smoking cessation.
Topics: Adrenergic Uptake Inhibitors; Affect; Animals; Antidepressive Agents, Tricyclic; Appetite; Humans; Nicotine; Nortriptyline; Receptors, Nicotinic; Smoking Cessation; Substance Withdrawal Syndrome | 1999 |
Development of major depression after treatment for smoking cessation.
Topics: Adult; Central Nervous System Stimulants; Chewing Gum; Combined Modality Therapy; Comorbidity; Depressive Disorder; Female; Humans; Incidence; Logistic Models; Male; Nicotine; Nortriptyline; Odds Ratio; Personality Inventory; Placebos; Polymethacrylic Acids; Polyvinyls; Prospective Studies; Psychotherapy; Smoking; Smoking Cessation; Smoking Prevention; Tobacco Use Cessation Devices; Tobacco Use Disorder; Treatment Outcome | 2000 |
Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Anti-Anxiety Agents; Anxiety; Behavior, Animal; Bromocriptine; Diazepam; Disease Models, Animal; Dopamine Antagonists; Dose-Response Relationship, Drug; Fear; Fluvoxamine; Haloperidol; Indophenol; Male; Maze Learning; Mecamylamine; Mice; Mice, Inbred ICR; Moclobemide; Motor Activity; Nicotine; Nicotinic Antagonists; Nortriptyline; Physostigmine; Picolinic Acids; Pyrrolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Social Behavior; Stress, Psychological | 2001 |
PHARMAC and tobacco control in New Zealand: two licensed funded options are already available.
Topics: Administration, Cutaneous; Bupropion; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Humans; Licensure; New Zealand; Nicotine; Nortriptyline; Practice Guidelines as Topic; Smoking Cessation; Tobacco Use Disorder; United States | 2005 |
What to do with a patient who smokes.
Topics: Antidepressive Agents; Bupropion; Central Nervous System Stimulants; Clonidine; Counseling; Hotlines; Humans; Nicotine; Nortriptyline; Physician's Role; Smoking; Smoking Cessation; Tobacco Use Disorder; United States | 2005 |
Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal.
Topics: Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Mecamylamine; Nicotine; Nortriptyline; Rats; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2007 |
Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzazepines; Bupropion; Cost-Benefit Analysis; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Theoretical; Netherlands; Nicotine; Nortriptyline; Quality of Life; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2008 |
Smoking cessation in primary care.
Topics: Drug Therapy, Combination; Evidence-Based Medicine; Humans; Nicotine; Nortriptyline; Primary Health Care; Randomized Controlled Trials as Topic; Smoking Cessation | 2008 |
[Summary of the practice guideline 'Smoking cessation' from the Dutch College of General Practitioners].
Topics: Bupropion; Chronic Disease; Family Practice; Female; Humans; Male; Motivation; Netherlands; Nicotine; Nortriptyline; Practice Patterns, Physicians'; Smoking Cessation; Social Support; Societies, Medical | 2008 |
[Smoking cessation with special focus on primary health care].
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Cardiovascular Diseases; Counseling; Evidence-Based Medicine; Family Practice; Humans; Nicotine; Nortriptyline; Outcome Assessment, Health Care; Primary Health Care; Psychotherapy, Group; Pulmonary Disease, Chronic Obstructive; Smoking; Smoking Cessation; Smoking Prevention | 2009 |
[Current and future medical drugs for smoking cessation].
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Cannabinoid Receptor Antagonists; Clinical Trials as Topic; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Piperidines; Pyrazoles; Quinoxalines; Rimonabant; Smoking Cessation; Tobacco Use Disorder; Vaccines; Varenicline | 2009 |
Current treatment options in smoking cessation.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Behavior Therapy; Benzazepines; Bupropion; Clonidine; Combined Modality Therapy; Counseling; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Patient Selection; Piperidines; Practice Guidelines as Topic; Pyrazoles; Quinoxalines; Rimonabant; Self-Help Groups; Smoking Cessation; Tobacco Use Disorder; United States; Vaccines; Varenicline | 2010 |
A real-life study of the effectiveness of different pharmacological approaches to the treatment of smoking cessation: re-discussing the predictors of success.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Bupropion; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multivariate Analysis; Nicotine; Nortriptyline; Retrospective Studies; Sex Factors; Smoking; Smoking Cessation; Time Factors; Treatment Outcome; Young Adult | 2011 |
Smoking cessation pharmacotherapy: a concise overview.
Topics: Adrenergic alpha-2 Receptor Agonists; Antidepressive Agents; Benzazepines; Bupropion; Clonidine; Humans; Nicotine; Nicotinic Agonists; Nortriptyline; Quinoxalines; Smoking; Smoking Cessation; Varenicline | 2011 |
Translating the smoking cessation properties of the antidepressant nortriptyline using reinforcing, discriminative and aversive stimulus effects of nicotine in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Conditioning, Operant; Discrimination Learning; Dose-Response Relationship, Drug; Male; Nicotine; Nortriptyline; Rats; Reinforcement Schedule; Self Administration; Smoking Cessation | 2012 |
Smoking cessation treatment outcomes among people with and without mental and substance use disorders: An observational real-world study.
Topics: Adult; Brazil; Bupropion; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Female; Humans; Male; Mental Disorders; Middle Aged; Nicotine; Nortriptyline; Outcome and Process Assessment, Health Care; Psychotherapy, Group; Smoking; Smoking Cessation; Substance-Related Disorders; Treatment Outcome | 2018 |